Skip to Main Content

Paper Details

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Nat Med
500
2019
MHC-I, MHC-II, PD1, anti-CTLA4, anti-PD1, melanoma, melanoma subtype, metastatic melanoma, patients, tumor, tumors, whole
Author NameAffiliation
Antje SuckerUniversity Hospital
Antje SuckerGerman Cancer Research Center
Jake ConwayBroad Institute of Harvard and MIT
Jake ConwayHarvard Medical School
Adam TracyBroad Institute of Harvard and MIT
Levi A GarrawayEli Lilly and Co.
Levi A GarrawayEli Lilly and Co.
Aviv RegevBroad Institute of Harvard and MIT
Aviv RegevBroad Institute of Harvard and MIT
Eliezer M Van AllenDana-Farber Cancer Institute
Eliezer M Van AllenBroad Institute of Harvard and MIT
Eliezer M Van AllenDana-Farber Cancer Institute
Eliezer M Van AllenBroad Institute of Harvard and MIT
Dirk SchadendorfUniversity Hospital
Dirk SchadendorfGerman Cancer Research Center
  • 1 - 15

Datasets

Release 1.2